Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

medicines_patent_pool2

The Medicines Patent Pool – five years on

February 25, 2016 Research and Development, Sales and Marketing

Introduction The Medicines Patent Pool (MPP) was founded five years ago as a program to improve access to affordable and …
Feature
gilead-sciences

Gilead announces HIV regimen trial results

February 25, 2016 Medical Communications, Research and Development, Sales and Marketing Gilead Sciences

Gilead Sciences has reported 48-week Phase III trial results suggesting fixed-dose Emtriva and tenofovir alafenamide (F/TAF) combinations matched its Truvada …
News
eli_lilly

European Commission approves Lilly’s Portrazza for NSCLC

February 24, 2016 Research and Development Eli Lilly, Portrazza

The European Commission has approved Eli Lilly’s Portrazza (necitumumab), in combination with gemcitabine and cisplatin chemotherapy, as a first-line treatment …
News
talc

J&J fined $72 million in talc cancer case

February 24, 2016 Research and Development, Sales and Marketing Johnson & Johnson

A Missouri jury has ruled that Johnson & Johnson must pay $72 million to the family of an Alabama woman, …
News
janssen_latest_logo_on_sign_closer

Janssen says cabotegravir/rilpivirine combo matches three-drug HIV maintenance therapy

February 24, 2016 Research and Development Janssen, ViiV

Janssen has announced 32-week data from an ongoing phase IIb study of an HIV regimen comprised of its rilpivirine and …
News
novo_nordisk

Novo Nordisk says Tresiba reduces hypoglycaemia risk vs Lantus

February 23, 2016 Manufacturing and Production, Research and Development Novo Nordisk

Novo Nordisk has announced trial results suggesting that its drug Tresiba (insulin degludec) carries a reduced risk of hypoglycaemia episodes, …
News
viiv_healthcare

ViiV completes BMS HIV pipeline purchase

February 23, 2016 Manufacturing and Production, Medical Communications, Research and Development Bristol-Myers Squibb, GSK, HIV, Pfizer, Shionogi, ViiV

ViiV Healthcare has completed its previously-announced acquisition of Bristol-Myers Squibb’s late-stage HIV R&D assets and its portfolio of preclinical and …
News
fda

Califf clears key hurdle to FDA top job

February 23, 2016 Manufacturing and Production, Medical Communications, Research and Development

Dr Robert Califf, President Obama’s nominee to head up the US Food and Drugs Administration as commissioner, has edged a …
News

Europe approves Bayer haemophilia drug

February 22, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Bayer, haemophilia a

Bayer has received approval from the European Commission for its haemophilia A drug Kovaltry (octocog alfa) in patients of all …
News
pharmafocus_march_front_cover

March edition of Pharmafocus live

February 22, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

The March 2016 edition of Pharmafocus is now live and available to read here.
News
amgen_ucb

Amgen and UCB announce positive romosozumab results

February 22, 2016 Medical Communications, Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, osteoporosis

Romosozumab development partners Amgen and UCB have announced positive top-line results from a Phase III study of the drug in postmenopausal …
News
sanofi

FDA to decide on Sanofi diabetes combo

February 22, 2016 Research and Development, Sales and Marketing Lantus, Sanofi

Sanofi will be looking to August for a decision on its new type 2 diabetes combo LixiLan (lixisenatide and Lantus), …
News
novartis_pic

Novartis drug PKC412 gets Breakthrough designation for AML

February 19, 2016 Medical Communications, Research and Development FDA, Novartis, acute myeloid leukaemia

Novartis’ PKC412 (midostaurin)  has become the latest in a sequence of FDA Breakthrough Therapy designations awarded this week- bagging the …
News

More evidence required for Alexion’s Kanuma, says NICE

February 18, 2016 Medical Communications, Research and Development Alexion, Kanuma, LAL-D, rare diseases

NICE says it needs additional trial data before it can recommend Alexion’s enzyme replacement therapy Kanuma (sebelipase alfa) for the …
News
antibiotics

Give GPs feedback on prescribing habits to reduce antibiotic use, says study

February 18, 2016 Medical Communications, Research and Development antimicrobial resistance

A trial of more than 1,500 GP practices has shown that sending general practitioners (GPs) letters giving feedback on their …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026